Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro

Umbreit,Claudia; Aderhold,Christoph; Faber,Anne; Sauter,Alexander; Hofheinz,Ralf-Dieter; Stern-Straeter,Jens; Hoermann,Karl; Schultz,Johannes  David

doi:10.3892/or.2014.3225

Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro

Authors:
- Claudia Umbreit
- Christoph Aderhold
- Anne Faber
- Alexander Sauter
- Ralf-Dieter Hofheinz
- Jens Stern-Straeter
- Karl Hoermann
- Johannes David Schultz
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, D-68167 Mannheim, Germany, Department of Hematology and Oncology, University Hospital Mannheim, D-68167 Mannheim, Germany
Published online on: May 30, 2014 https://doi.org/10.3892/or.2014.3225
Pages: 668-676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide. The growth and invasion of HNSCC are strongly influenced by the extracellular matrix (ECM), which is modified by matrix metalloproteinases (MMPs). The MMP family is still relevant to cancer research, as it promotes malignant transformation, cell proliferation and modulation of angiogenesis even in the early stages of cancer. The proteolytic processing of bioactive molecules by MMP-14 (MT1-MMP) causes severe abnormalities in connective tissue, defective angiogenesis and premature death. MMP-2 (gelatinase A) and MMP-14 also play a role in degradation of basement membrane and cell carcinoma invasion. Imatinib blocks the PTK receptor c-kit and forestalls its PTK activity. The aim of the present study was to investigate the expression pattern of MMP-14 and MMP-2 in human papilloma virus (HPV)-negative and p16-positive SCC and to evaluate the chemosensitivity of the tumour cells to the chemotherapeutic agents, imatinib and 5-fluorouracil (5-FU). We incubated the SCC cell lines with imatinib (18 and 30 µmol/ml) and 5-FU (1 and 5 µmol/ml) and detected MMP-14 and MMP-2 by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) after 48, 72, 120, 192 and 240 h. We detected expression of MMP-2 and MMP-14 in all incubated tumour cell lines. With imatinib in particular, we found a reliable trend towards decreased MMP-2 and MMP-14 expression levels in p16-positive and p16-negative SCC tumour cell lines in addition to an induced apoptotic effect. We found statistically significant imatinib-induced suppression of MMP-2- and MMP-14, dependent on the incubation time and the cell line. We detected a significant suppression of MMP-2 and MMP-14 especially in p16-negative HNSCC14C cells after prolonged treatment time with imatinib. Dose escalation of imatinib and 5-FU had no statistically significant effect on the expression of MMP-2 or MMP-14. The p16-positive SCC cells exhibited higher expression of total protein. We detected a significant suppression of MMP-2 and MMP-14 in all the incubated SCC cell lines, partially after treatment with imatinib. We found higher suppression of MMP-2 in the CERV196 cells after incubation with imatinib. We detected a reliable trend towards increased chemosensitivity of p16-positive tumour cells in vitro after treatment with imatinib. Extended studies and clinical trials are needed to further investigate these findings in HPV-associated HNSCC.

View Figures

View References

1	Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar
2	Bodnar M, Szylberg L, Kazmierczak W and Marszalek A: Differentiated expression of membrane type metalloproteinases (MMP-14, MMP-15) and pro-MMP2 in laryngeal squamous cell carcinoma. A novel mechanism J Oral Pathol Med. 42:267–274. 2013. View Article : Google Scholar : PubMed/NCBI
3	Oliveira LR and Ribeiro-Silva A: Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 40:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
4	de Vicente JC, Lequerica-Fernandez P, Santamaria J and Fresno MF: Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med. 36:415–424. 2007.PubMed/NCBI
5	Massano J, Regateiro FS, Januario G and Ferreira A: Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 102:67–76. 2006. View Article : Google Scholar : PubMed/NCBI
6	Schultz JD, Rotunno S, Riedel F, et al: Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/β expression in squamous cell carcinoma of the head and neck in vitro. Int J Oncol. 38:1001–1012. 2011.PubMed/NCBI
7	Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY and Yun PY: Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg. 35:1005–1010. 2006. View Article : Google Scholar : PubMed/NCBI
8	Sepiashvili L, Hui A, Ignatchenko V, et al: Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. Mol Cell Proteomics. 11:1404–1415. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11:21–28. 2010.PubMed/NCBI
10	Nair S and Pillai MR: Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers. Oral Dis. 11:350–359. 2005. View Article : Google Scholar : PubMed/NCBI
11	Sudhoff HH, Schwarze HP, Winder D, et al: Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol. 268:1541–1547. 2011. View Article : Google Scholar : PubMed/NCBI
12	Schultz JD, Sommer JU, Hoedt S, et al: Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Oncol Rep. 27:270–280. 2012.
13	Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 14:467–475. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wang Z, Sturgis EM, Zhang Y, et al: Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 131:E251–E258. 2012. View Article : Google Scholar : PubMed/NCBI
15	Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer. 103:1843–1849. 2005.PubMed/NCBI
16	Tezal M, Scannapieco FA, Wactawski-Wende J, et al: Local inflammation and human papillomavirus status of head and neck cancers. Arch Otolaryngol Head Neck Surg. 138:669–675. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 233:706–720. 2005. View Article : Google Scholar : PubMed/NCBI
18	Tester AM, Ruangpanit N, Anderson RL and Thompson EW: MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis. 18:553–560. 2000. View Article : Google Scholar
19	Stamenkovic I: Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 200:448–464. 2003. View Article : Google Scholar : PubMed/NCBI
20	Al-Azri AR, Gibson RJ, Keefe DM and Logan RM: Matrix metalloproteinases: do they play a role in mucosal pathology of the oral cavity? Oral Dis. 19:347–359. 2013. View Article : Google Scholar : PubMed/NCBI
21	Martins VL, Caley M and O’Toole EA: Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res. 351:255–268. 2013. View Article : Google Scholar : PubMed/NCBI
22	de Andres MC, Kingham E, Imagawa K, et al: Epigenetic regulation during fetal femur development: DNA methylation matters. PLoS One. 8:e549572013.PubMed/NCBI
23	Tamamura R, Nagatsuka H, Siar CH, et al: Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 115:113–119. 2013.
24	Folgueras AR, Pendas AM, Sanchez LM and Lopez-Otin C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kaimal R, Aljumaily R, Tressel SL, et al: Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 73:2457–2467. 2013. View Article : Google Scholar : PubMed/NCBI
26	Mallis A, Teymoortash A, Mastronikolis NS, Werner JA and Papadas TA: MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol. 269:639–642. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gorogh T, Beier UH, Baumken J, et al: Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck. 28:31–39. 2006. View Article : Google Scholar : PubMed/NCBI
28	Bran B, Bran G, Hormann K and Riedel F: The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol. 34:255–261. 2009.PubMed/NCBI
29	Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:925–932. 2000.PubMed/NCBI
30	Levitzki A: Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 53:161–185. 2013. View Article : Google Scholar : PubMed/NCBI
31	Angelini S, Ravegnini G, Fletcher JA, Maffei F and Hrelia P: Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. Pharmacogenomics. 14:941–956. 2013. View Article : Google Scholar : PubMed/NCBI
32	Rutkowski P and Gronchi A: Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors. Oncologist. 18:689–696. 2013. View Article : Google Scholar : PubMed/NCBI
33	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
34	Klussmann JP, Preuss SF and Speel EJ: Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications. HNO. 57:113–122. 2009.(In German).
35	Scanlon CS, Van Tubergen EA, Inglehart RC and D’Silva NJ: Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
36	Koontongkaew S: The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 4:66–83. 2013. View Article : Google Scholar : PubMed/NCBI
37	Stahtea XN, Roussidis AE, Kanakis I, et al: Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer. 121:2808–2814. 2007. View Article : Google Scholar : PubMed/NCBI
38	Tsao AS, Liu S, Fujimoto J, et al: Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 6:2104–2111. 2011. View Article : Google Scholar : PubMed/NCBI
39	Popow-Wozniak A, Wozniakowska A, Kaczmarek L, Malicka-Blaszkiewicz M and Nowak D: Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration. Eur J Pharmacol. 667:66–73. 2011. View Article : Google Scholar
40	Shiau MY, Fan LC, Yang SC, et al: Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One. 8:e544232013. View Article : Google Scholar : PubMed/NCBI
41	Cardeal LB, Boccardo E, Termini L, et al: HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One. 7:e335852012. View Article : Google Scholar : PubMed/NCBI
42	Richter P, Umbreit C, Franz M, et al: EGF/TGFbeta1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J Oral Pathol Med. 40:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
43	Qiao B, Johnson NW and Gao J: Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J Oncol. 37:663–668. 2010.
44	Umbreit C, Aderhold C, Faber A, et al: Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Anticancer Res. 33:2457–2465. 2013.
45	Yasumatsu R, Nakashima T and Komune S: Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil in head and neck squamous cell carcinoma in vitro. J Oncol. 2012:6496052012. View Article : Google Scholar : PubMed/NCBI
46	Milano G and Etienne MC: Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 4:301–306. 1994. View Article : Google Scholar : PubMed/NCBI
47	Jiang W, Lu Z, He Y and Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res. 3:395–399. 1997.
48	Kawasaki G, Yoshitomi I, Yanamoto S, Yamada S, Mizuno A and Umeda M: Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82. Anticancer Res. 31:3521–3526. 2011.
49	Tamatani T, Ferdous T, Takamaru N, et al: Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells. Int J Oncol. 41:1148–1156. 2012.PubMed/NCBI
50	Wang P, Nie J and Pei D: The hemopexin domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) is not required for its activation of proMMP2 on cell surface but is essential for MT1-MMP-mediated invasion in three-dimensional type I collagen. J Biol Chem. 279:51148–51155. 2004. View Article : Google Scholar : PubMed/NCBI
51	Weng CJ, Chen MK, Lin CW, Chung TT and Yang SF: Single nucleotide polymorphisms and haplotypes of MMP-14 are associated with the risk and pathological development of oral cancer. Ann Surg Oncol. 19(Suppl 3): S319–S327. 2012. View Article : Google Scholar : PubMed/NCBI
52	Sabeh F, Li XY, Saunders TL, Rowe RG and Weiss SJ: Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem. 284:23001–23011. 2009. View Article : Google Scholar : PubMed/NCBI
53	Zarrabi K, Dufour A, Li J, et al: Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem. 286:33167–33177. 2011. View Article : Google Scholar : PubMed/NCBI